Vaxcyte (PCVX) Stock Overview
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PCVX Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Vaxcyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.75 |
| 52 Week High | US$118.62 |
| 52 Week Low | US$27.66 |
| Beta | 1.04 |
| 1 Month Change | -1.67% |
| 3 Month Change | -6.86% |
| 1 Year Change | -71.68% |
| 3 Year Change | 32.13% |
| 5 Year Change | -38.72% |
| Change since IPO | 21.41% |
Recent News & Updates
Recent updates
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Jul 07
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity
Mar 31Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Mar 24Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy
Jan 15We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Dec 08Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Sep 06We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Aug 24Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?
May 10Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Dec 27We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Sep 12Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation
May 30We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth
Dec 22Vaxcyte appoints new CBO, CMO
Oct 11Shareholder Returns
| PCVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.4% | 1.0% | 1.5% |
| 1Y | -71.7% | -8.1% | 18.6% |
Return vs Industry: PCVX underperformed the US Biotechs industry which returned -8.1% over the past year.
Return vs Market: PCVX underperformed the US Market which returned 18.6% over the past year.
Price Volatility
| PCVX volatility | |
|---|---|
| PCVX Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PCVX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PCVX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 414 | Grant Pickering | vaxcyte.com |
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria.
Vaxcyte, Inc. Fundamentals Summary
| PCVX fundamental statistics | |
|---|---|
| Market cap | US$4.12b |
| Earnings (TTM) | -US$547.49m |
| Revenue (TTM) | n/a |
Is PCVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$547.50m |
| Earnings | -US$547.49m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PCVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/22 21:10 |
| End of Day Share Price | 2025/09/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxcyte, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Thomas Shrader | BTIG |
| Carter Gould | Cantor Fitzgerald & Co. |